Stocktoria
MIRA PHARMACEUTICALS, INC. MIRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-08-03
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M |
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M | -$5.6M |
| Total assets | $11.1M | $2.9M | $4.9M | $858,074 |
| Total liabilities | $702,068 | $723,349 | $558,097 | $1.5M |
| Shareholders' equity | $10.4M | $2.2M | $4.4M | -$596,232 |
| Ratios | ||||
| Return on assets | -94.1% | -268.6% | -242.9% | -822.6% |
| Return on equity | -100.5% | -357.0% | -273.9% | 1183.8% |
| Current ratio | 15.75 | 3.99 | 8.70 | 0.36 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001904286 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.